MASLD: The Silent Liver Crisis Affecting a Third of the World

Metabolic dysfunction-associated steatotic liver disease, or MASLD, now affects roughly one in three people globally. The condition was renamed in 2023 to better reflect its causes and reduce stigma linked to its previous label. Unlike alcohol-related liver damage, MASLD stems from metabolic issues that lead to fat buildup in the liver.

MASLD was once known as nonalcoholic fatty liver disease (NAFLD). Experts updated the name to clarify that metabolic dysfunction—not alcohol—drives the condition. By 2023, around 1.3 billion people worldwide were officially diagnosed, partly due to improved testing methods like elastography and biomarker analysis. New guidelines, such as those from the European Association for the Study of the Liver (EASL) in 2024, have since standardised diagnosis further.

The disease often starts with few noticeable signs. Fatigue and abdominal discomfort are the most frequent symptoms, but some patients also report increased thirst, sleep disturbances, or digestive issues. Without intervention, MASLD can worsen into a more severe form called metabolic dysfunction-associated steatohepatitis (MASH). Early detection remains critical, as treatment can halt progression and, in some cases, even reverse liver damage.

MASLD has become the leading cause of chronic liver disease worldwide. Its prevalence highlights the growing impact of metabolic disorders on global health.

Better diagnostic tools and updated medical guidelines have made identifying MASLD more accurate. With early intervention, patients can manage the condition and avoid severe liver damage. The shift in terminology also helps reduce confusion about its non-alcoholic origins.